<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163244">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02062996</url>
  </required_header>
  <id_info>
    <org_study_id>IRB14-00016</org_study_id>
    <nct_id>NCT02062996</nct_id>
  </id_info>
  <brief_title>Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption</brief_title>
  <official_title>The Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption During Functional Endoscopic or Turbinate Reduction Surgery and From the Nasal Mucosa During Operative Dentistry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Richard Cartabuke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxymetazoline is an α-adrenergic agonist that is commonly used as a topical sympathomimetic
      agent in over-the-counter decongestant sprays. It is used extensively at Nationwide
      Children's Hospital for surgical procedures to produce vasoconstriction and reduce bleeding.
      Although there is generally limited vascular absorption, when administered in larger doses,
      uptake of oxymetazoline can lead to significant systemic hemodynamic effects. The NCH
      anesthesia department recently reported a case of oxymetazoline induced postoperative
      hypertension in a three-year-old child following inferior turbinate reduction and
      adenoidectomy. Current practice at NCH is to soak pledgets with full strength oxymetazoline
      and insert a varying number of pledgets during surgical procedures or instill oxymetazoline
      drops into the nose prior to nasotracheal intubation. There is no pediatric data regarding
      the method of administration and the absorption of oxymetazoline or the dose-response
      relationship of oxymetazoline serum levels on blood pressure and heart rate. These studies
      would be the first to determine safe and appropriate doses of oxymetazoline in the pediatric
      population.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Oxymetazoline plasma concentration</measure>
    <time_frame>5, 10, 20, 45, 90 &amp; 150 mins. after dosing</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Every 2-5 mins. for a maximum of 240 mins.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessing for bradycardia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Every 2-5 mins. for a maximum of 240 mins.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessing for hypertension.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dental Anesthesia</condition>
  <condition>Nasal Surgical Procedures</condition>
  <condition>Intranasal Drug Administration</condition>
  <arm_group>
    <arm_group_label>ENT - full strength</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Full strength oxymetazoline pledgets packed in the nose (total volume 20 ml).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ENT - 1/2 strength</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>½ strength oxymetazoline pledgets packed in the nose (total volume 20 ml).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DENTAL - Full strength 1.0 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Full strength oxymetazoline 1.0 mL to each naris (total =1000 mcg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DENTAL - Full strength 0.5 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Full strength oxymetazoline 0.5 mL to each naris (total = 500 mcg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DENTAL - ½ strength 0.5 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>½ strength oxymetazoline 0.5 mL to each naris (total = 250 mcg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxymetazoline</intervention_name>
    <arm_group_label>ENT - full strength</arm_group_label>
    <arm_group_label>ENT - 1/2 strength</arm_group_label>
    <arm_group_label>DENTAL - Full strength 1.0 mL</arm_group_label>
    <arm_group_label>DENTAL - Full strength 0.5 mL</arm_group_label>
    <arm_group_label>DENTAL - ½ strength 0.5 mL</arm_group_label>
    <other_name>Afrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ages 2 through 12 yrs.

          -  Scheduled for: operative dentistry, functional endoscopic sinus surgery, or turbinate
             reduction (with or without tonsillectomy and/or adenoidectomy).

        Exclusion Criteria:

          -  Treatment with oral decongestants or antihistamines within 24 hours of surgery.

          -  Taking anticoagulants.

          -  History of nasal trauma.

          -  History of epistaxis (nose bleeds).

          -  History of hypertension or cardiac disease.

          -  Allergy to oxymetazoline.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Cartabuke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie Rice, RN</last_name>
    <phone>614-355-3142</phone>
    <email>julie.rice@nationwidechildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>N'Diris Barry, RN</last_name>
    <phone>614-355-3467</phone>
    <email>ndiris.barry@nationwidechildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 12, 2014</lastchanged_date>
  <firstreceived_date>February 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>Richard Cartabuke</investigator_full_name>
    <investigator_title>Co-Director Outpatient Anesthesia Services</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
